BoneKEy-Osteovision | Perspective
Bisphosphonates and γδ t-cells: New insights into old drugs
Keith Thompson
Michael J Rogers
DOI:10.1138/20060224
Abstract
Bisphosphonates (BPs) are now well established as front-line treatments for post-menopausal osteoporosis, Paget's disease and tumor-associated osteolysis and hypercalcemia. Since the basic pharmacology and mechanisms of action of these bone-targeting agents have been reviewed in detail elsewhere (), we summarize new insights into their mode of inhibition of FPP synthase, concepts of their anti-resorptive effects on osteoclasts and, in particular, discuss their recently-discovered effects on γδ T-cells and prospects for their future use as immune therapies.
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License.